Open AccessPhase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer
Author(s) -
Akinori Watanabe,
Mitsuhiro Kida,
Shiro Miyazawa,
Tomohisa Iwai,
Kosuke Okuwaki,
Toru Kaneko,
Hiroshi Yamauchi,
Miyoko Takezawa,
Hiroshi Inoue,
Wasaburo Koizumi
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i19.5979
Subject(s) - gemcitabine , medicine , neutropenia , cisplatin , chemotherapy , febrile neutropenia , gastroenterology , biliary tract cancer , cancer , tegafur , phases of clinical research , deoxycytidine , biliary tract
To evaluate the dose-limiting toxicities (DLTs) and determine the maximum-tolerated dose (MTD) and recommended dose (RD) of combination chemotherapy with gemcitabine, cisplatin and S-1 which is an oral fluoropyrimidine pro-drug in patients with advanced biliary tract cancer.